No Data
No Data
No Data
No Data
No Data
XORTX Therapeutics Announces Publication of Key Research in ADPKD in Peer-reviewed Journal
XORTX Therapeutics Inc. (XRTX.V and NASDAQ: XRTX), a pharmaceutical company developing therapies to treat progressive kidney disease, on Monday announced a research paper showing for the first time th
MT NewswiresApr 22 19:44
XORTX Therapeutics Inc. Gets FDA Orphan Drug Designation For Oxypurinol For Treatment Of Autosomal Dominant Polycystic Kidney Disease
XORTX Therapeutics Inc. Gets FDA Orphan Drug Designation For Oxypurinol For Treatment Of Autosomal Dominant Polycystic Kidney Disease
BenzingaApr 20, 2023 23:50
Xortx Therapeutics Inc Filed For Mixed Shelf Of Up To $50M
Xortx Therapeutics Inc Filed For Mixed Shelf Of Up To $50M
Benzinga Real-time NewsJan 27, 2023 19:51
Xortx Stock Surges ~60% as Potential Kidney Disease Drug Shows Promise in Early Stage Study
Seeking AlphaJan 19, 2023 21:18
Xortx Stock Soars 40% as Kidney Disease Drug Shows Promise in Bridging Study
Xortx Therapeutics (NASDAQ:XRTX) said its proprietary formulation of oxypurinol showed a substantial increase in oral bioavailability provided with food compared to the fasted state in a pharmacokinet
Seeking AlphaAug 22, 2022 20:19
Press Release: XORTX Therapeutics Announces Annual and Special Meeting of Shareholders
XORTX Therapeutics Announces Annual and Special Meeting of Shareholders CALGARY, Alberta, Nov. 23, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (TSXV: XRTX | NASD
Dow Jones NewswiresNov 23, 2021 20:01
No Data
No Data